Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Tuberculosis and Polio Vaccines Being Tested for Limited Protection Against Coronavirus

By HospiMedica International staff writers
Posted on 15 Jun 2020
As the COVID-19 pandemic continues to spread globally, scientists are now conducting tests to see if vaccines meant for tuberculosis (TB) and polio can provide protection from the deadly coronavirus.

According to a report by The Washington Post, tests are currently underway to determine if the TB vaccine called bacillus Calmette-Guerin, or BCG, can slow the novel coronavirus. More...
The BCG vaccine has already received approval from the Food and Drug Administration (FDA) and has a long history of safe usage. A team of researchers led by Dr Jeffrey D Cirillo, a professor of microbial pathogenesis and immunology at Texas A&M Health Science Center, is now testing the TB vaccine to see if it can reduce the severity of coronavirus.

“This vaccine has a very broad ability to strengthen your immune response. We call it ‘trained immunity. This could make a huge difference in the next two to three years while the development of a specific vaccine is developed for COVID-19,” said Cirillo in a statement from Texas A&M Health Science Center newsletter.

Azra Raza, a professor of medicine at Columbia University Medical Center, told The Washington Post that BCG could improve people's ability to fight pathogens, even in patients who are given the vaccine for another approved use that is bladder cancer. “Researchers have looked at developing countries where mortality rates are lower, in these countries BCG vaccine is widely used. It’s not like they’re not getting the infection. The rate (of positive infections) is high. But they’re just not dying. It is raging through, but they’re not dying of it,” stated Raza in the report by The Washington Post.

According to The Washington Post report, a group of scientists is also testing the polio vaccine oral OPV and its effect on slowing COVID-19. “Vaccines developed against TB and polio have already been used in millions of people and could offer a low-risk way to rev up the body’s first line of defense, the innate immune system, against a broad array of pathogens, including the coronavirus,” the group said.

Robert Gallo, a world-renowned researcher who co-discovered that HIV is the cause of AIDS, said that OPV had a strong safety record. “This is not complicated, the science is there to support the idea, and we need to act fast,” said Gallo in a statement by the University of Maryland.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.